Badrinath Konety presents Blue light cystoscopy for the diagnosis of bladder cancer: Results from the US prospective multicenter registry.  Blue light cystoscopy (BLC) using hexaminolevulinate HCL (Cysview®) has been previously shown to improve the detection of non-muscle-invasive bladder cancer (NMIBC).  The objective of this study was to evaluate the detection of malignant lesions in a heterogenous group of patients in the real world setting and document the change in risk category due to upstaging or upgrading.  Dr. Konety summarizes the key points about the registry and the study findings.  Blue Light Cystoscopy with hexaminolevulinate HCL significantly increases detection rates of CIS and papillary lesions compared to White Light Cystoscopy alone and can result in upstaging or upgrading in about 14% of patients. Further, he says repeat use of Cysview® for Blue Light Cystoscopy is safe.



Biography:

Badrinath Konety, MD, MBA, Dr. Badrinath Konety serves as CEO of the University of Minnesota Physicians as well as Vice Dean for Clinical Affairs at the University of Minnesota Medical School. He is also a professor in the Department of Urology and Director of the Institute for Prostate and Urologic Cancers.